troglitazone has been researched along with Hyperglycemia, Postprandial in 16 studies
Troglitazone: A chroman and thiazolidinedione derivative that acts as a PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS (PPAR) agonist. It was formerly used in the treatment of TYPE 2 DIABETES MELLITUS, but has been withdrawn due to hepatotoxicity.
Hyperglycemia, Postprandial: Abnormally high BLOOD GLUCOSE level after a meal.
| Excerpt | Relevance | Reference |
|---|---|---|
| "In conclusion, PPARγ agonist, troglitazone improved glucose transport SGLT2 dysfunction and subsequent glucagon dysregulation in alpha cell under hyperglycemia." | 7.85 | The effect of PPARγ agonist on SGLT2 and glucagon expressions in alpha cells under hyperglycemia. ( Jung, HS; Kim, M; Kim, TK; Kim, TN; Kwon, MJ; Lee, EJ; Lee, SH; Park, JH; Rhee, BD; Shin, HM, 2017) |
| "Metformin-treated rats gained significantly less weight." | 5.29 | Prevention of hyperglycemia in the Zucker diabetic fatty rat by treatment with metformin or troglitazone. ( Burant, CF; Polonsky, KS; Pugh, W; Sreenan, S; Sturis, J, 1996) |
| "In conclusion, PPARγ agonist, troglitazone improved glucose transport SGLT2 dysfunction and subsequent glucagon dysregulation in alpha cell under hyperglycemia." | 3.85 | The effect of PPARγ agonist on SGLT2 and glucagon expressions in alpha cells under hyperglycemia. ( Jung, HS; Kim, M; Kim, TK; Kim, TN; Kwon, MJ; Lee, EJ; Lee, SH; Park, JH; Rhee, BD; Shin, HM, 2017) |
| "To determine the relationship between hypoglycemic activity and body weight gain induced by insulin sensitizers, we compared the effects of thiazolidinedione analogs (troglitazone and pioglitazone) and the oxadiazolidinedione analog (Z)-1,4-bis4[(3,5-dioxo-1,2,4-oxadiazolidin-2-yl)methyl]phen oxy¿but-2-ene (YM440) in diabetic db/db mice." | 3.70 | The novel hypoglycemic agent YM440 normalizes hyperglycemia without changing body fat weight in diabetic db/db mice. ( Hirayama, R; Kurosaki, E; Nakano, R; Shibasaki, M; Shikama, H; Shimaya, A, 2000) |
| "Diabetes mellitus is associated with alterations in a number of key metabolic pathways." | 2.40 | Drug administration in patients with diabetes mellitus. Safety considerations. ( Cooper, ME; Gilbert, RE; Krum, H, 1998) |
| "Troglitazone (TGZ) treatment, beginning at 6 weeks of age, prevented the hyperglycemia, the hyperlipidemia, and the increase in 11beta-HSD-1." | 1.32 | Increased expression and activity of 11beta-HSD-1 in diabetic islets and prevention with troglitazone. ( Agarwal, AK; Duplomb, L; Lee, Y; Park, BH; Takaishi, K; Unger, RH; Wang, MY, 2004) |
| "Treatment with troglitazone resulted in a significant, specific decrease in type I collagen along with a slight decrease in laminin production in both medium conditions." | 1.31 | Troglitazone suppresses the secretion of type I collagen by mesangial cells in vitro. ( Johnson, JH; McCarthy, KJ; Routh, RE, 2002) |
| "Metformin-treated rats gained significantly less weight." | 1.29 | Prevention of hyperglycemia in the Zucker diabetic fatty rat by treatment with metformin or troglitazone. ( Burant, CF; Polonsky, KS; Pugh, W; Sreenan, S; Sturis, J, 1996) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 6 (37.50) | 18.2507 |
| 2000's | 8 (50.00) | 29.6817 |
| 2010's | 2 (12.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Berger, J | 1 |
| Bailey, P | 1 |
| Biswas, C | 1 |
| Cullinan, CA | 1 |
| Doebber, TW | 1 |
| Hayes, NS | 1 |
| Saperstein, R | 1 |
| Smith, RG | 1 |
| Leibowitz, MD | 1 |
| Kim, M | 1 |
| Lee, EJ | 1 |
| Shin, HM | 1 |
| Jung, HS | 1 |
| Kim, TK | 1 |
| Kim, TN | 1 |
| Kwon, MJ | 1 |
| Lee, SH | 1 |
| Rhee, BD | 1 |
| Park, JH | 1 |
| Liang, YJ | 1 |
| Jian, JH | 1 |
| Chen, CY | 1 |
| Hsu, CY | 1 |
| Shih, CY | 1 |
| Leu, JG | 1 |
| Wu, L | 1 |
| Davies, GF | 1 |
| Roesler, WJ | 1 |
| Juurlink, BH | 1 |
| Duplomb, L | 1 |
| Lee, Y | 1 |
| Wang, MY | 1 |
| Park, BH | 1 |
| Takaishi, K | 1 |
| Agarwal, AK | 1 |
| Unger, RH | 1 |
| Sreenan, S | 1 |
| Sturis, J | 1 |
| Pugh, W | 1 |
| Burant, CF | 1 |
| Polonsky, KS | 1 |
| Okuno, A | 1 |
| Tamemoto, H | 1 |
| Tobe, K | 1 |
| Ueki, K | 1 |
| Mori, Y | 1 |
| Iwamoto, K | 1 |
| Umesono, K | 1 |
| Akanuma, Y | 1 |
| Fujiwara, T | 2 |
| Horikoshi, H | 2 |
| Yazaki, Y | 1 |
| Kadowaki, T | 2 |
| Gilbert, RE | 1 |
| Cooper, ME | 1 |
| Krum, H | 1 |
| Skyler, JS | 1 |
| Shimaya, A | 1 |
| Kurosaki, E | 1 |
| Nakano, R | 1 |
| Hirayama, R | 1 |
| Shibasaki, M | 1 |
| Shikama, H | 1 |
| Murao, S | 1 |
| Hirata, K | 1 |
| Ishida, T | 1 |
| Takahara, J | 1 |
| Stiefelhagen, P | 1 |
| McCarthy, KJ | 2 |
| Routh, RE | 2 |
| Shaw, W | 1 |
| Walsh, K | 1 |
| Welbourne, TC | 1 |
| Johnson, JH | 2 |
| Wada, M | 1 |
| Fukuda, K | 1 |
| Fukami, M | 1 |
| Yoshioka, S | 1 |
| Yoshioka, T | 1 |
2 reviews available for troglitazone and Hyperglycemia, Postprandial
| Article | Year |
|---|---|
Drug administration in patients with diabetes mellitus. Safety considerations.
Topics: Acarbose; Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive Ag | 1998 |
[Hypoglycemic agents to improve insulin resistance].
Topics: Adipocytes; Animals; Cell Differentiation; Chromans; Diabetes Mellitus, Type 2; Disease Models, Anim | 2000 |
14 other studies available for troglitazone and Hyperglycemia, Postprandial
| Article | Year |
|---|---|
Thiazolidinediones produce a conformational change in peroxisomal proliferator-activated receptor-gamma: binding and activation correlate with antidiabetic actions in db/db mice.
Topics: Animals; Blood Glucose; COS Cells; Cricetinae; Diabetes Mellitus; Hyperglycemia; Hypertriglyceridemi | 1996 |
The effect of PPARγ agonist on SGLT2 and glucagon expressions in alpha cells under hyperglycemia.
Topics: Animals; Cells, Cultured; Chromans; Gene Expression Regulation; Glucagon; Glucagon-Secreting Cells; | 2017 |
L-165,041, troglitazone and their combination treatment to attenuate high glucose-induced receptor for advanced glycation end products (RAGE) expression.
Topics: Apoptosis; Chromans; Cytokines; Drug Interactions; Gene Expression Regulation; Glucose; HEK293 Cells | 2013 |
Regulation of the glyoxalase pathway in human brain microvascular endothelium: effects of troglitazone and tertiary butylhydroperoxide.
Topics: Animals; Brain; Cells, Cultured; Cerebrovascular Circulation; Chromans; Dose-Response Relationship, | 2002 |
Increased expression and activity of 11beta-HSD-1 in diabetic islets and prevention with troglitazone.
Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 1; Animals; Animals, Genetically Modified; Blotting, Weste | 2004 |
Prevention of hyperglycemia in the Zucker diabetic fatty rat by treatment with metformin or troglitazone.
Topics: Age Factors; Animals; Body Weight; Chromans; Diabetes Mellitus, Type 2; Fatty Acids, Nonesterified; | 1996 |
Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats.
Topics: Adipocytes; Adipose Tissue; Animals; Apoptosis; Blood Glucose; Blotting, Northern; Body Weight; Chro | 1998 |
Targeted glycemic control in type 2 diabetes.
Topics: Aged; Algorithms; Anti-Obesity Agents; Biguanides; Blood Glucose; Blood Glucose Self-Monitoring; Chr | 1998 |
The novel hypoglycemic agent YM440 normalizes hyperglycemia without changing body fat weight in diabetic db/db mice.
Topics: 3T3 Cells; Adipose Tissue; Animals; Blood Glucose; Cell Differentiation; Chromans; Diabetes Mellitus | 2000 |
Troglitazone in progesterone derivative-induced impairment of glucose tolerance.
Topics: Aged; Antineoplastic Agents, Hormonal; Blood Glucose; Chromans; Diabetes Mellitus, Type 2; Female; G | 2000 |
[New development in diabetes therapy. 35th Annual Meeting of the German Diabetes Society, Munich, May 5-June 3, 2000].
Topics: Chromans; Diabetes Mellitus, Type 2; Germany; Humans; Hyperglycemia; Hypoglycemic Agents; Insulin; P | 2000 |
Troglitazone halts diabetic glomerulosclerosis by blockade of mesangial expansion.
Topics: Animals; Basement Membrane; Body Weight; Chondroitin Sulfate Proteoglycans; Chromans; Diabetes Melli | 2000 |
Troglitazone suppresses the secretion of type I collagen by mesangial cells in vitro.
Topics: Animals; Cells, Cultured; Chromans; Clofibrate; Collagen Type I; Extracellular Matrix Proteins; Glom | 2002 |
Characterization of CS-045, a new oral antidiabetic agent, II. Effects on glycemic control and pancreatic islet structure at a late stage of the diabetic syndrome in C57BL/KsJ-db/db mice.
Topics: Administration, Oral; Animals; Blood Glucose; Chromans; Diabetes Mellitus; Glucagon; Hyperglycemia; | 1991 |